Beta-Alanine in Sports Performance Trials: What the Evidence Shows

Beta-alanine (β-alanine; 3-aminopropionic acid) is a non-essential amino acid that serves as the rate-limiting precursor to carnosine (β-alanyl-L-histidine) synthesis in skeletal muscle. Carnosine concentrations in human skeletal muscle range from approximately 15–50 mmol/kg dry weight depending on fibre type composition and training status. Type II (fast-twitch) fibres contain substantially higher carnosine concentrations than Type I (slow-twitch) fibres, a distribution consistent with carnosine's proposed role in high-intensity anaerobic exercise. **The buffering mechanism** During intense exercise, anaerobic glycolysis generates ATP alongside hydrogen ions (H⁺). Accumulation of H⁺ — reducing intracellular pH — is associated with impaired cross-bridge cycling, reduced calcium sensitivity of contractile proteins, and inhibition of key glycolytic enzymes. Carnosine acts as an intracellular H⁺ buffer: its imidazole ring accepts H⁺ over the physiologically relevant pH range (6.5–7.0). By attenuating the decline in intracellular pH during intense exercise, elevated carnosine is proposed to delay the onset of muscular fatigue. Carnosine also functions as an antioxidant, a chelator of transition metal ions, and a substrate for carnosinase, but the pH-buffering function is the mechanism most directly relevant to exercise performance. **Harris et al. (2006) — PMID: 16554972** The foundational loading study by Harris and colleagues established the kinetics of beta-alanine supplementation on muscle carnosine. Participants received a range of beta-alanine doses over 4–10 weeks. The study confirmed several key findings that have since been replicated: (1) beta-alanine availability, not histidine availability, is the rate-limiting step in carnosine synthesis; (2) muscle carnosine increases are dose-dependent — in one controlled supplementation condition, participants receiving 4.8 g/day showed approximately 40% elevation in vastus lateralis carnosine content at 4 weeks and approximately 64% at 10 weeks; (3) a slow-release (sustained-release) formulation produced equivalent carnosine loading with reduced frequency and intensity of paraesthesia compared to immediate-release doses. Harris et al. also characterised the pharmacokinetics of oral beta-alanine absorption, finding peak plasma concentrations within 30–45 minutes of ingestion, followed by uptake into skeletal muscle over hours. The washout kinetics — muscle carnosine declining back towards baseline over weeks following cessation — were also documented in subsequent work by the same group. For the full item-level breakdown of carnosine loading research, see the [beta-alanine item page](/items/beta-alanine).